Shares of TG Therapeutics Inc (NASDAQ: TGTX), a clinical-stage biopharmaceutical company, has witnessed a strong upward price momentum in the past few trading sessions and ended at its new intraday high yesterday. The company’s shares jumped over 7% during the last two consecutive trading days with significant number of shares exchanging hands. In the last trading session, TGTX was among the top gainers in the U.S. healthcare sector after climbing 12.9% and ended at its 52-week high of $9.69 while recording huge volumes of 675,350 shares. During the last 5-trading sessions, TGTX gained 7.4% with 5-day average trading volumes of 527,028 shares, while the stock accumulated over 81% in the past one month with 30-day average volumes of 465,700 shares. The stock has rallied over 148% year-to-date.
Company Description:
TG Therapeutics Inc (NASDAQ: TGTX) is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.
1-Year Stock Chart:
Source: Bloomberg
